2014

CareFusion Reports Third Quarter Rise in Revenue, Earnings - Revenue increased 4 percent to $867 million and operating income increased 70 percent to $146 million

- GAAP diluted earnings per share (EPS) from continuing operations increased to $0.38, or $0.42 on an adjusted basis

- Company raises the lower end of 2011 guidance for adjusted EPS from continuing operations to $1.60, narrowing the range to $1.60 to $1.65

SAN DIEGO, May 5, 2011 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the three and nine months ended March 31, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

"Our business performed well in the quarter, driving revenue and operating earnings growth year-over-year and expanding margins through a favorable product mix and disciplined expense control," said Kieran Gallahue, chairman and CEO. "Our earnings for the quarter outperformed our internal expectations, giving us confidence to raise the lower end of our adjusted EPS guidance and narrow the range to $1.60 to $1.65. Additionally, we continue to make progress in our efforts to optimize our product portfolio. We recently completed the divestiture of two businesses and acquired Vestara, expanding our core Pyxis medication management portfolio to include technology that enables hospitals to automate the segregation of pharmaceutical waste."

CareFusion's reported results compare to the three and nine month periods ended March 31, 2010.

Results from the company's International Surgical Products (ISP) business, which had been included in the Medical Technologies and Services segment and was divested in April 2011, have been classified as discontinued operations in the accompanying financial tables. Reported results for continuing operations and comparisons to prior periods exclude the historical results of the ISP business.

Third Quarter Results

Revenue for the third quarter of fiscal 2011 increased 4 percent to $867 million on a reported basis and 3 percent on a constant currency basis, driven primarily by increased sales in the Infusion, Infection Prevention and Dispensing businesses. Operating income was $146 million and income from continuing operations was $86 million, or $0.38 per diluted share. Excluding nonrecurring items, adjusted operating income increased $51 million to $155 million and adjusted income from continuing operations increased $41 million to $94 million, or $0.42 per diluted share. The adjusted tax rate for the quarter was 31.7 percent.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D), restructuring and acquisition integration charges and gain on the sale of assets totaled $301 million, or 35 percent of total revenue. Excluding $9 million of nonrecurring items, adjusted operating expenses totaled $292 million, or 34 percent of total revenue. Adjusted SG&A expenses were $253 million and R&D investments totaled $39 million.

Critical Care Technologies

Revenue for the Critical Care Technologies segment increased 5 percent to $661 million driven by Infusion product sales, including core growth and a contribution from the May 2010 acquisition of Medegen, and an increase in Dispensing sales. These increases were offset by an expected decrease in Respiratory sales due to a weak post H1N1 environment. Segment profit increased 49 percent to $115 million, and adjusted segment profit increased 43 percent to $129 million.

Medical Technologies and Services

Revenue for the Medical Technologies and Services segment decreased 1 percent to $206 million, driven by the loss of revenue from the company's May 2010 divestiture of the Research Services business, which was essentially offset by increased sales from the Infection Prevention and Medical Specialties businesses. Net of this divestiture, revenue growth would have been 8 percent. Segment profit increased 78 percent to $16 million, and adjusted segment profit increased 86 percent to $26 million.

Nine-Month Results

Revenue for the first nine months of fiscal 2011 increased 1 percent to $2.56 billion. Operating income increased to $347 million and income from continuing operations was $195 million, or $0.87 per diluted share. Excluding nonrecurring items, adjusted operating income increased $47 million to $423 million and adjusted income from continuing operations increased $32 million to $253 million, or $1.13 per diluted share.

Operating expenses totaled $958 million or 37 percent of total revenue. Excluding $76 million of nonrecurring items, adjusted operating expenses totaled $882 million, or 34 percent of total revenue. Adjusted SG&A expenses were $767 million, and R&D investments totaled $115 million.

Critical Care Technologies

Revenue for the Critical Care Technologies segment increased 2 percent to $1.96 billion. Segment profit increased 3 percent to $298 million, or 9 percent to $357 million on an adjusted basis.

Medical Technologies and Services

Revenue for the Medical Technologies and Services segment decreased 2 percent to $602 million. Segment profit was even with the prior year at $34 million, and increased 35 percent to $66 million on an adjusted basis.

Fiscal 2011 Outlook

CareFusion reaffirmed its fiscal 2011 revenue guidance of low single digit growth over fiscal 2010 revenue of $3.5 billion. In addition, the company narrowed its outlook for adjusted diluted EPS from continuing operations for fiscal 2011 to a range of $1.60 to $1.65, the upper end of its previously provided guidance range of $1.58 to $1.65. The guidance is based on an assumed diluted weighted average outstanding share count of approximately 225 million.

Conference Call

CareFusion will host a conference call today at 2 p.m. PDT (5 p.m. EDT) to discuss earnings results for the third quarter fiscal 2011.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 901-5247 within the U.S. or (617) 786-4501 from outside the U.S., and use the access code 55257170. A replay of the conference call will be available from 5 p.m. PDT (8 p.m. EDT) on May 5 through 8:59 p.m. PDT (11:59 p.m. EDT) on May 12 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 Internationally and using the access code 91057852.

About CareFusion

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AirLife™, AVEA® and LTV® series of ventilators and respiratory products, ChloraPrep® skin prep products, MedMined™ services for data mining surveillance, V. Mueller® and Snowden-Pencer® surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows: “adjusted operating expenses”, “adjusted SG&A expenses” and “adjusted operating income”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring gain on the sale of assets; “adjusted income from continuing operations”, “adjusted diluted earnings per share from continuing operations” and “adjusted effective tax rate”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets, and nonrecurring tax items; and “adjusted segment profit”, which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, SG&A expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, effective tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarter and nine month periods ended March 31, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure “adjusted diluted earnings per share from continuing operations” on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share from continuing operations. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion’s future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion’s financial condition and results of operations is included as Exhibit 99.3 to CareFusion’s report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2011.

Cautions Concerning Forward-looking Statements

The CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of May 5, 2011. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CAREFUSION CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)
















Quarter Ended


Nine Months Ended





March 31,


March 31,

(in millions, except per share amounts)


2011


2010


2011


2010












Revenue

$

867

$

837

$

2,564

$

2,542

Cost of Products Sold


420


423


1,259


1,263



Gross Margin


447


414


1,305


1,279












Selling, General and Administrative Expenses


263


285


805


834

Research and Development Expenses


39


42


115


115

Restructuring and Acquisition Integration Charges


14


1


53


7

Gain on the Sale of Assets


(15)


-


(15)


-



Operating Income


146


86


347


323












Interest Expense and Other, Net


19


27


62


89

Income Before Income Tax


127


59


285


234

Provision for Income Tax


41


72


90


123

Income (Loss) from Continuing Operations


86


(13)


195


111

Discontinued Operations










Impairment/Loss from the Disposal of Discontinued Businesses, Net of Tax


(40)


-


(40)


(8)


Income (Loss) from the Operations of Discontinued Businesses, Net of Tax


(1)


4


4


39

Income (Loss) from Discontinued Operations, Net of Tax


(41)


4


(36)


31












Net Income (Loss)

$

45

$

(9)

$

159

$

142












Per Share Amounts: (1)




















Basic Earnings (Loss) per Common Share:










Continuing Operations

$

0.39

$

(0.06)

$

0.88

$

0.50


Discontinued Operations

$

(0.18)

$

0.02

$

(0.16)

$

0.14


Basic Earnings (Loss) per Common Share

$

0.20

$

(0.04)

$

0.71

$

0.64












Diluted Earnings (Loss) per Common Share:










Continuing Operations

$

0.38

$

(0.06)

$

0.87

$

0.50


Discontinued Operations

$

(0.18)

$

0.02

$

(0.16)

$

0.14


Diluted Earnings (Loss) per Common Share

$

0.20

$

(0.04)

$

0.71

$

0.64












Weighted-Average Number of Common Shares Outstanding:










Basic


223.0


221.6


222.6


221.4


Diluted (2)


225.6


221.6


224.6


222.7

____________










(1)


Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented.


(2)


Dilutive shares outstanding equal basic shares outstanding for the quarter ended March 31, 2010 as the impact would be anti-dilutive.



CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)
















Quarter Ended March 31, 2011







Discontinued


Nonrecurring



(in millions, except per common share amounts)


GAAP


Operations (1)


Items (2)


Adjusted (3)












Revenue (4)

$

867

$

-

$

-

$

867

Cost of Products Sold


420


-


-


420



Gross Margin


447




-


447












Selling, General and Administrative Expenses


263


-


(10)


253

Research and Development Expenses


39


-


-


39

Restructuring and Acquisition Integration Charges


14


-


(14)


-

Gain on the Sale of Assets


(15)


-


15


-



Operating Income


146


-


9


155












Interest Expense and Other, Net


19


-


-


19

Income Before Income Tax


127


-


9


136

Provision for Income Tax


41


-


1


42

Income from Continuing Operations


86


-


8


94

Discontinued Operations










Impairment Loss from Discontinued Businesses, Net of Tax


(40)


40


-


-


Loss from the Operations of Discontinued Businesses, Net of Tax


(1)


1


-


-

Loss from Discontinued Operations, Net of Tax


(41)


41


-


-





-







Net Income

$

45

$

41

$

8

$

94












Per Share Amounts: (5)









Basic Earnings per Common Share

$

0.20

$

0.18

$

0.04

$

0.42

Diluted Earnings per Common Share

$

0.20

$

0.18

$

0.03

$

0.42












Weighted-Average Number of Common Shares Outstanding:










Basic


223.0


223.0


223.0


223.0


Diluted


225.6


225.6


225.6


225.6












Effective Tax Rate


32.7%


n/a


17.9%


31.7%

____________










(1)


Reflects the impact of the divestiture of the International Surgical Products (ISP) business.


(2)


Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items.  


(3)


Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.


(4)


Revenues increased $30 million for the quarter ended March 31, 2011 compared to 2010, or a $27 million increase on a constant currency basis.


(5)


Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.



CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)
















Nine Months Ended March 31, 2011







Discontinued


Nonrecurring



(in millions, except per common share amounts)


GAAP


Operations (1)


Items (2)


Adjusted (3)












Revenue (4)

$

2,564

$

-

$

-

$

2,564

Cost of Products Sold


1,259


-


-


1,259



Gross Margin


1,305


-


-


1,305












Selling, General and Administrative Expenses


805


-


(38)


767

Research and Development Expenses


115


-


-


115

Restructuring and Acquisition Integration Charges


53


-


(53)


-

Gain on the Sale of Assets


(15)


-


15


-



Operating Income


347


-


76


423












Interest Expense and Other, Net


62


-


-


62

Income Before Income Tax


285


-


76


361

Provision for Income Taxes


90


-


18


108

Income from Continuing Operations


195


-


58


253

Discontinued Operations










Impairment Loss from Discontinued Businesses, Net of Tax


(40)


40


-


-


Income from the Operations of Discontinued Businesses, Net of Tax


4


(4)


-


-

Loss from Discontinued Operations, Net of Tax


(36)


36


-


-












Net Income

$

159

$

36

$

58

$

253












Per Share Amounts: 5









Basic Earnings per Common Share

$

0.71

$

0.16

$

0.26

$

1.14

Diluted Earnings per Common Share

$

0.71

$

0.16

$

0.26

$

1.13












Weighted-Average Number of Common Shares Outstanding:










Basic


222.6


222.6


222.6


222.6


Diluted


224.6


224.6


224.6


224.6












Effective Tax Rate


31.7%


n/a


23.8%


30.0%

____________










(1)


Reflects the impact of the divestiture of the International Surgical Products (ISP) business.


(2)


Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items.  


(3)


Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.


(4)


Revenues increased $22 million for the nine months ended March 31, 2011 compared to 2010, or a $26 million increase on a constant currency basis.


(5)


Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.



CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)
















Quarter Ended March 31, 2010







Discontinued


Nonrecurring



(in millions, except per common share amounts)


GAAP


Operations (1)


Items (2)


Adjusted (3)












Revenue

$

837

$

-

$

-

$

837

Cost of Products Sold


423


-


-


423



Gross Margin


414


-


-


414












Selling, General and Administrative Expenses


285


-


(17)


268

Research and Development Expenses


42


-


-


42

Restructuring and Acquisition Integration Charges


1


-


(1)


-



Operating Income


86


-


18


104












Interest Expense and Other, Net


27


-


-


27

Income Before Income Tax


59


-


18


77

Provision for Income Tax


72


-


(48)


24

Income (Loss) from Continuing Operations


(13)


-


66


53

Discontinued Operations










Income from the Operations of Discontinued Businesses, Net of Tax


4


(4)


-


-

Income from Discontinued Operations, Net of Tax


4


(4)


-


-












Net Income (Loss)

$

(9)

$

(4)

$

66

$

53












Per Share Amounts: (4)









Basic Earnings (Loss) per Common Share

$

(0.04)

$

(0.02)

$

0.30

$

0.24

Diluted Earnings (Loss) per Common Share

$

(0.04)

$

(0.02)

$

0.30

$

0.24












Weighted-Average Number of Common Shares Outstanding:










Basic


221.6


221.6


221.6


221.6


Diluted (5)


221.6


221.6


221.6


221.6












Effective Tax Rate


122.8%


n/a


(258.3)%


31.7%

____________










(1)


Reflects the impact of the divestiture of the International Surgical Products (ISP) business.


(2)


Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.


(3)


Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.


(4)


Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.


(5)


Dilutive shares outstanding equal basic shares outstanding for the quarter ended March 31, 2010 as the impact would be anti-dilutive.



CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)
















Nine Months Ended March 31, 2010







Discontinued


Nonrecurring



(in millions, except per common share amounts)


GAAP


Operations (1)


Items (2)


Adjusted (3)












Revenue

$

2,542

$

-

$

-

$

2,542

Cost of Products Sold


1,263


-


-


1,263



Gross Margin


1,279


-


-


1,279












Selling, General and Administrative Expenses


834


-


(46)


788

Research and Development Expenses


115


-


-


115

Restructuring and Acquisition Integration Charges


7


-


(7)


-



Operating Income


323


-


53


376












Interest Expense and Other, Net


89


-


(22)


67

Income Before Income Tax


234


-


75


309

Provision for Income Tax


123


-


(35)


88

Income from Continuing Operations


111


-


110


221

Discontinued Operations










Loss from the Disposal of Discontinued Businesses, Net of Tax


(8)


8


-


-


Income from the Operations of Discontinued Businesses, Net of Tax


39


(39)


-


-

Income from Discontinued Operations, Net of Tax


31


(31)


-


-












Net Income

$

142

$

(31)

$

110

$

221












Per Share Amounts: (4)









Basic Earnings per Common Share

$

0.64

$

(0.14)

$

0.50

$

1.00

Diluted Earnings per Common Share

$

0.64

$

(0.14)

$

0.50

$

0.99












Weighted-Average Number of Common Shares Outstanding:










Basic


221.4


221.4


221.4


221.4


Diluted


222.7


222.7


222.7


222.7












Effective Tax Rate


52.8%


n/a


(46.4)%


28.6%

____________










(1)


Reflects the impact of (a) removing certain businesses that manufacture and sell surgical and exam gloves, surgical drapes and apparel and fluid management products in the U.S. market that were previously part of the Clinical and Medical Products segment of Cardinal Health and were retained by Cardinal Health upon the spinoff, (b) the divestiture of the Company’s audiology business and (c) the divestiture of the International Surgical Products (ISP) business.


(2)


Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring charges related to the bridge loan entered into in connection with the spinoff, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.


(3)


Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.


(4)


Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.



CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)
















Quarter Ended March 31, 2011








Nonrecurring



(in millions)



GAAP


Items (1)


Adjusted (2)

Critical Care Technologies









Revenue


$

661

$

-

$

661


Operating Income (3)



115


14


129











Medical Technologies and Services









Revenue


$

206

$

-

$

206


Operating Income (3)



16


10


26


















Nine Months Ended March 31, 2011








Nonrecurring



(in millions)



GAAP


Items (1)


Adjusted (2)

Critical Care Technologies









Revenue


$

1,962

$

-

$

1,962


Operating Income (3)



298


59


357











Medical Technologies and Services









Revenue


$

602

$

-

$

602


Operating Income (3)



34


32


66


















Quarter Ended March 31, 2010








Nonrecurring



(in millions)



GAAP (4)


Items (1)


Adjusted (2)

Critical Care Technologies









Revenue


$

629

$

-

$

629


Operating Income



77


13


90











Medical Technologies and Services









Revenue


$

208

$

-

$

208


Operating Income



9


5


14


















Nine Months Ended March 31, 2010








Nonrecurring



(in millions)



GAAP (4)


Items (1)


Adjusted (2)

Critical Care Technologies









Revenue


$

1,928

$

-

$

1,928


Operating Income



289


38


327











Medical Technologies and Services









Revenue


$

614

$

-

$

614


Operating Income



34


15


49



____________


(1)


Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.


(2)


Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.


(3)


The $15 million gain on the sale of assets associated with the March 2011 divestiture of our OnSite Services business has not been allocated to segment results for the quarter and nine months ended March 31, 2011.


(4)


Previously reported amounts have been adjusted to reflect discontinued operations.



SOURCE CareFusion Corp.



RELATED LINKS
http://www.carefusion.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.